| Medical and Health Sciences | Lifetime | 419 | IT 16 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 126 | IT 8 | 99.98 |
| Epidemiology | Lifetime | 32 | IT 2 | 99.95 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 120 | IT 7 | 99.64 |
| Pathology and Forensic Medicine | Lifetime | 296 | IT 15 | 98.92 |
| Cardiology and Cardiovascular Medicine | Lifetime | 895 | IT 40 | 97.94 |
| Nephrology | Lifetime | 399 | IT 19 | 96.38 |
| Hepatology | Lifetime | 469 | IT 34 | 95.60 |
| Epidemiology | 2021-2025 | 11 | IT 1 | 99.95 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 54 | IT 4 | 99.31 |
| Hepatology | 2021-2025 | 96 | IT 8 | 96.62 |
| Medical Physiology | 2021-2025 | 655 | IT 30 | 89.82 |
| Liver Disease Diagnosis and Treatment | Lifetime | 16 | IT 1 | 99.95 |
| Diet, Metabolism, and Disease | Lifetime | 9 | IT 1 | 99.88 |
| Alcohol Consumption and Health Effects | Lifetime | 8 | IT 1 | 99.75 |
| Liver Disease and Transplantation | Lifetime | 45 | IT 3 | 99.78 |
| Pancreatitis Pathology and Treatment | Lifetime | 38 | IT 5 | 99.67 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 31 | IT 6 | 98.65 |
| Lipid metabolism and disorders | Lifetime | 67 | IT 2 | 98.93 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 197 | IT 6 | 99.22 |
| Cardiovascular Function and Risk Factors | Lifetime | 453 | IT 24 | 99.17 |
| Diet and metabolism studies | Lifetime | 557 | IT 21 | 98.97 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 65 | IT 4 | 98.08 |
| Cardiovascular Disease and Adiposity | Lifetime | 238 | IT 10 | 98.66 |
| Diabetes Treatment and Management | Lifetime | 371 | IT 27 | 98.61 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 360 | IT 13 | 98.34 |
| Liver Diseases and Immunity | Lifetime | 195 | IT 17 | 98.28 |
| Vitamin D Research Studies | Lifetime | 298 | IT 11 | 97.83 |
| Metabolism, Diabetes, and Cancer | Lifetime | 850 | IT 42 | 97.15 |
| Diabetes Management and Research | Lifetime | 952 | IT 55 | 97.08 |
| Folate and B Vitamins Research | Lifetime | 936 | IT 38 | 94.62 |
| Chronic Kidney Disease and Diabetes | Lifetime | 793 | IT 43 | 95.88 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 510 | IT 24 | 94.31 |
| Blood properties and coagulation | Lifetime | 812 | IT 49 | 93.89 |
| Case Reports on Hematomas | Lifetime | 884 | IT 48 | 67.96 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 15 | IT 3 | 99.91 |
| Liver Disease and Transplantation | 2021-2025 | 9 | IT 1 | 99.82 |
| Pancreatitis Pathology and Treatment | 2021-2025 | 7 | IT 3 | 99.68 |
| Diet, Metabolism, and Disease | 2021-2025 | 6 | IT 1 | 99.83 |
| Diet and metabolism studies | 2021-2025 | 56 | IT 8 | 99.08 |
| Alcohol Consumption and Health Effects | 2021-2025 | 25 | IT 2 | 98.61 |
| Diabetes Treatment and Management | 2021-2025 | 164 | IT 9 | 98.15 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 161 | IT 6 | 95.03 |
| Lipid metabolism and disorders | 2021-2025 | 63 | IT 6 | 92.08 |
| Liver Diseases and Immunity | 2021-2025 | 133 | IT 19 | 94.84 |
| Hepatitis C virus research | 2021-2025 | 433 | IT 31 | 93.38 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 431 | IT 33 | 88.44 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 987 | IT 99 | 90.97 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 656 | IT 26 | 87.96 |
| Sphingolipid Metabolism and Signaling | 2021-2025 | 884 | IT 51 | 53.61 |
